Dysplasia has a differential diagnosis: Distinguishing genuine myelodysplastic syndromes (MDS) from mimics, imitators, copycats and impostors

Current Hematologic Malignancy Reports

Volumn 7, Issue 4, 2012, Pages 310-320

  Steensma, David P ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Aplastic anemia; Copper deficiency; Differential diagnosis; Dysplasia; Leukemia; Molecular diagnostics; Myelodysplastic syndromes (MDS); Nutritional deficiency; Pathology; Sideroblastic anemia

Indexed keywords

METHYLMALONIC ACID; PYRIDOXINE;

APLASTIC ANEMIA; ARTICLE; COPPER DEFICIENCY; CYANOCOBALAMIN DEFICIENCY; CYTOPENIA; DIFFERENTIAL DIAGNOSIS; DYSPLASIA; ERYTHROLEUKEMIA; HUMAN; IDIOPATHIC CYTOPENIA; IDIOPATHIC DYSPLASIA; KARYOTYPE; MOLECULAR DIAGNOSIS; MYELODYSPLASTIC SYNDROME; NUTRITIONAL DEFICIENCY; SIDEROBLASTIC ANEMIA; THROMBOCYTOPENIA;

BONE MARROW; BONE MARROW DISEASES; CELL COUNT; DIAGNOSIS, DIFFERENTIAL; HUMANS; MYELODYSPLASTIC SYNDROMES; REFERENCE VALUES; WORLD HEALTH ORGANIZATION;

EID: 84872171995     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-012-0140-3     Document Type: Article

References (85)

1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976;33(4):451-8.
2. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51(2):189-99.
3. Vardiman JW. Hematopathological concepts and controversies in the diagnosis and classification of myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2006:199-204. doi:2006/1/199 [pii] 10.1182/asheducation- 2006.1.199.
4. Dickstein JI, Vardiman JW. Issues in the pathology and diagnosis of the chronic myeloproliferative disorders and the myelodysplastic syndromes. Am J Clin Pathol. 1993;99(4):513-25.
5. Naqvi K, Jabbour E, Bueso-Ramos C, Pierce S, Borthakur G, Estrov Z, et al. Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers. Blood. 2011;118(17):4690-3. doi:10.1182/blood-2011-03-342642.
6. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17(12):3835-49.
7. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-51. doi:10.1182/blood-2009-03-209262.
8. Brunning RD, Orazi A, Germing U, Le Beau MM, Porwit A, Baumann I, et al. Myelodysplastic syndromes/neoplasms, overview. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al., editors.WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: IARC Press; 2008. p. 89-93.
9. Bain BJ. The bone marrow aspirate of healthy subjects. Br J Haematol. 1996;94(1):206-9. (Pubitemid 26232567)
10. Parmentier S, Schetelig J, Lorenz K, Kramer M, Ireland R, Schuler U, et al. Assessment of dysplastic hematopoiesis: lessons from healthy bone marrow donors. Haematologica. 2012;97(5):723-30. doi:10.3324/haematol.2011.056879.
11. Della Porta MG, Picone C, Pascutto C, Malcovati L, Tamura H, Handa H, et al. Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study. Haematologica. 2012;97(8):1209-17. doi:10.3324/haematol.2011. 048421.
12. Valent P, Horny HP, Bennett JM, Fonatsch C, Germing U, Greenberg P, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference. Leuk Res. 2007;31(6):727-36. doi:10.1016/j.leukres.2006.11.009. ICUS is a useful term to describe cytopenias that are not yet able to be diagnosed definitively asMDS but that could be MDS and might clearly turn into MDS over time. This workshop report discusses current definition of ICUS and appropriate diagnostic evaluation. It is appropriate to follow such patients over time, as in most cases the illness will eventually "declare" itself.
13. van de Loosdrecht AA, Alhan C, Bene MC, Della Porta MG, Drager AM, Feuillard J, et al. Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes. Haematologica. 2009;94(8):1124-34. doi:10.3324/haematol.2009.005801.
14. Westers TM, Ireland R, KernW, Alhan C, Balleisen JS, Bettelheim P, et al. Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia. 2012;26 (7):1730-41. doi:10.1038/leu.2012.30leu201230[pii].
15. Marisavljevic D, Rolovic Z, Ludoski-Pantic M, Djordjevic V, Novak A. Spontaneous remission in adults with primary myelodysplastic syndromes: incidence and characteristics of patients. Med Oncol. 2005;22(4):407-10. doi:10.1385/MO:22:4:407.
16. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med. 2011;364(26):2496-506. doi:10.1056/NEJMoa1013343. More than 25 recurrent somatic mutations have been described in MDS. This report describes phenotype-genotype correlations of 18 of these mutations in a large cohort of MDS primary samples. The presence of such mutations may confirm oligoclonal hematopoiesis.
17. Yoshida K, Sanada M, Shiraishi Y, Nowak D, Nagata Y, Yamamoto R, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011;478(7367):64-9. doi:10.1038/nature10496. In some cases of pure sideroblastic anemia, it can be difficult to be confident about whether the patient has typical acquired RARS or a late presentation of one of the forms of congenital sideroblastic anemia. Microcytosis can be a clue to an ALAS2 germline mutations, but the finding of a somatic SF3B1 mutation clinches the diagnosis as MDS-RARS.
18. Khalidi HS, Chang KL, Medeiros LJ, Brynes RK, Slovak ML, Murata-Collins JL, et al. Acute lymphoblastic leukemia. Survey of immunophenotype, French-American-British classification, frequency of myeloid antigen expression, and karyotypic abnormalities in 210 pediatric and adult cases. Am J Clin Pathol. 1999;111(4):467-76.
19. Valent P, Horny HP. Minimal diagnostic criteria for myelodysplastic syndromes and separation from ICUS and IDUS: update and open questions. Eur J Clin Investig. 2009;39(7):548-53. doi:10.1111/j.1365-2362.2009.02151.x.
20. Wimazal F, Fonatsch C, Thalhammer R, Schwarzinger I, Mullauer L, Sperr WR, et al. Idiopathic cytopenia of undetermined significance (ICUS) versus low risk MDS: the diagnostic interface. Leuk Res. 2007;31(11):1461-8. doi:10.1016/j.leukres.2007.03.015. (Pubitemid 47632790)
21. Valent P, Jager E, Mitterbauer-Hohendanner G, Mullauer L, Schwarzinger I, Sperr WR, et al. Idiopathic bone marrow dysplasia of unknown significance (IDUS): definition, pathogenesis, follow up, and prognosis. Am J Cancer Res. 2011;1(4):531-41.
22. Hanson CA, Hoyer JD, Zakko L, Hodnefield JM, Steensma DP. Is idiopathic cytopenia of undetermined significance (ICUS) a valid clinical concept? A longitudinal clinicopathological study [Abstract P092, presented at the 10th International Symposium on Myelodysplastic Syndromes, Patras, Greece, May 2009.]. Leukemia Research 2009;33(Supplement 1).
23. Schroeder T, Ruf L, Bernhardt A, Hildebrandt B, Aivado M, Aul C, et al. Distinguishing myelodysplastic syndromes (MDS) from idiopathic cytopenia of undetermined significance (ICUS): HUMARA unravels clonality in a subgroup of patients. Ann Oncol. 2010;21 (11):2267-71. doi:10.1093/annonc/mdq233.
24. Walter MJ, Shen D, Ding L, Shao J, Koboldt DC, Chen K, et al. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med. 2012;366(12):1090-8. doi:10.1056/NEJMoa1106968. Whole genome sequencing confirms that even in MDS without excess blasts, multiple missense and nonsense somatic mutations are already present and the neoplastic clones usually dominate the marrow.
25. Pedersen-Bjergaard J, Pedersen M, Roulston D, Philip P. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood. 1995;86(9):3542-52.
26. Pedersen-Bjergaard J, Andersen MK, AndersenMT, Christiansen DH. Genetics of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia. 2008;22(2):240-8. doi:10.1038/sj.leu.2405078. (Pubitemid 351250527)
27. Laurie CC, Laurie CA, Rice K, Doheny KF, Zelnick LR, McHugh CP, et al. Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nat Genet. 2012;44(6):642-50. doi:10.1038/ng.2271.
28. Li W, Vijg J. Measuring genome instability in aging -A minireview. Gerontology. 2012;58(2):129-38. doi:10.1159/000334368.
29. Leone G, Pagano L, Ben-Yehuda D, Voso MT. Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica. 2007;92(10):1389-98.
30. Steele JM, Sung L, Klaassen R, Fernandez CV, Yanofsky R,Wu J, et al. Disease progression in recently diagnosed patients with inherited marrow failure syndromes: a Canadian Inherited Marrow Failure Registry (CIMFR) report. Pediatr Blood Cancer. 2006;47(7):918-25. doi:10.1002/pbc.20876.
31. Mehta PA, Harris RE, Davies SM, Kim MO, Mueller R, Lampkin B, et al. Numerical chromosomal changes and risk of development of myelodysplastic syndrome-Acute myeloid leukemia in patients with Fanconi anemia. Cancer Genet Cytogenet. 2010;203(2):180-6. doi:10.1016/j.cancergencyto.2010.07.127.
32. Scheinberg P, Young NS. How I treat acquired aplastic anemia. Blood. 2012;120(6):1185-96. doi:10.1182/blood-2011-12-274019.
33. Dokal I.Dyskeratosis congenita. HematologyAmSoc Hematol Educ Program. 2011;2011:480-6. doi:10.1182/asheducation-2011.1.480.
34. Beel K, Vandenberghe P. G-CSF receptor (CSF3R) mutations in X-linked neutropenia evolving to acute myeloid leukemia or myelodysplasia. Haematologica. 2009;94(10):1449-52. doi:10.3324/haematol.2009.009001.
35. Gohring G, Karow A, Steinemann D, Wilkens L, Lichter P, Zeidler C, et al. Chromosomal aberrations in congenital bone marrow failure disorders-An early indicator for leukemogenesis? Ann Hematol. 2007;86(10):733-9. doi:10.1007/s00277-007-0337-z. (Pubitemid 47337936)
36. Link DC, Kunter G, Kasai Y, Zhao Y, Miner T, McLellan MD, et al. Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia. Blood. 2007;110(5):1648-55. doi:10.1182/blood-2007-03-081216.
37. Palmblad J, Papadaki HA. Chronic idiopathic neutropenias and severe congenital neutropenia. Curr Opin Hematol. 2008;15(1):8-14. doi:10.1097/MOH. 0b013e3282f172d3.
38. Vandenberghe P, Beel K. Severe congenital neutropenia, a genetically heterogeneous disease group with an increased risk ofAML/MDS. Pediatr Rep. 2011;3 Suppl 2:e9. doi:10.4081/pr.2011.s2.e9.
39. Song WJ, Sullivan MG, Legare RD, Hutchings S, Tan X, Kufrin D, et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet. 1999;23(2):166-75. doi:10.1038/13793.
40. Hahn CN, Chong CE, Carmichael CL, Wilkins EJ, Brautigan PJ, Li XC, et al. Heritable GATA2 mutations associated with familial myelodysplastic syndrome and acute myeloid leukemia. Nat Genet. 2011;43(10):1012-7. doi:10.1038/ng.913.
41. Iolascon A, Russo R, Delaunay J. Congenital dyserythropoietic anemias. Curr Opin Hematol. 2011;18(3):146-51. doi:10.1097/MOH.0b013e32834521b0.
42. Head DR, Kopecky K, Bennett JM, Grenier K, Morrison FS, Miller KB, et al. Pathogenetic implications of internuclear bridging in myelodysplastic syndrome. An Eastern Cooperative Oncology Group/Southwest Oncology Group Cooperative Study. Cancer. 1989;64(11):2199-202.
43. Albers CA, Cvejic A, Favier R, Bouwmans EE, Alessi MC, Bertone P, et al. Exome sequencing identifies NBEAL2 as the causative gene for gray platelet syndrome. Nat Genet. 2011;43 (8):735-7. doi:10.1038/ng.885.
44. Toyama K, Ohyashiki K, Yoshida Y, Abe T, Asano S, Hirai H, et al. Clinical and cytogenetic findings of myelodysplastic syndromes showing hypocellular bone marrow or minimal dysplasia, in comparison with typical myelodysplastic syndromes. Int J Hematol. 1993;58(1-2):53-61.
45. Barrett J, Saunthararajah Y, Molldrem J. Myelodysplastic syndrome and aplastic anemia: distinct entities or diseases linked by a common pathophysiology? Semin Hematol. 2000;37(1):15-29.
46. Afable 2nd MG, Wlodarski M, Makishima H, Shaik M, Sekeres MA, Tiu RV, et al. SNP array-based karyotyping: differences and similarities between aplastic anemia and hypocellular myelodysplastic syndromes. Blood. 2011;117(25):6876-84. doi:10.1182/blood-2010-11-314393. Aplastic anemia can be challenging to distinguish from hypoplastic MDS. SNP arrays can aid in this distinction, as discussed in the text. SNP arrays are now commercially available from several reference labs and can be ordered by clinicians in ambiguous cases.
47. Afable 2nd MG, Tiu RV, Maciejewski JP. Clonal evolution in aplastic anemia. Hematology Am Soc Hematol Educ Program. 2011;2011:90-5. doi:10.1182/asheducation-2011.1.90.
48. Tiu R, Gondek L, O'Keefe C, Maciejewski JP. Clonality of the stem cell compartment during evolution of myelodysplastic syndromes and other bone marrow failure syndromes. Leukemia. 2007;21(8):1648-57. doi:10.1038/sj.leu.2404757.
49. Marsh JC, Ball SE, Cavenagh J, Darbyshire P, Dokal I, Gordon-Smith EC, et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol. 2009;147(1):43-70. doi:10.1111/j.1365-2141.2009.07842.x.
50. Walne AJ, Dokal A, Plagnol V, Beswick R, Kirwan M, de la Fuente J, et al. Exome sequencing identifies MPL as a causative gene in familial aplastic anemia. Haematologica. 2012;97(4):524-8. doi:10.3324/haematol.2011.052787.
51. Molldrem JJ, Leifer E, Bahceci E, Saunthararajah Y, Rivera M, Dunbar C, et al. Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med. 2002;137(3):156-63.
52. Passweg JR, Giagounidis AA, Simcock M, Aul C, Dobbelstein C, Stadler M, et al. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care-SAKK 33/9. J Clin Oncol. 2011;29 (3):303-9. doi:10.1200/JCO.2010.31.2686.
53. Saunthararajah Y, Nakamura R, Nam JM, Robyn J, Loberiza F, Maciejewski JP, et al. HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood. 2002;100(5):1570-4. (Pubitemid 34925129)
54. Killick SB, Mufti G, Cavenagh JD, Mijovic A, Peacock JL, Gordon-Smith EC, et al. A pilot study of antithymocyte globulin (ATG) in the treatment of patients with 'low-risk' myelodysplasia. Br J Haematol. 2003;120(4):679-84.
55. Dhodapkar MV, Li CY, Lust JA, Tefferi A, Phyliky RL. Clinical spectrum of clonal proliferations of T-large granular lymphocytes: a T-cell clonopathy of undetermined significance? Blood. 1994;84 (5):1620-7. (Pubitemid 24273033)
56. Saunthararajah Y, Molldrem JL, Rivera M, Williams A, Stetler-Stevenson M, Sorbara L, et al. Coincident myelodysplastic syndrome and T-cell large granular lymphocytic disease: clinical and pathophysiological features. Br J Haematol. 2001;112(1):195-200.
57. Huh YO, Medeiros LJ, Ravandi F, Konoplev S, Jorgensen JL, Miranda RN. T-cell large granular lymphocyte leukemia associated with myelodysplastic syndrome: a clinicopathologic study of nine cases. Am J Clin Pathol. 2009;131(3):347-56. doi:10.1309/AJCP6YHI1JEXAWAP.
58. Maciejewski JP, O'Keefe C, Gondek L, Tiu R. Immune-mediated bone marrow failure syndromes of progenitor and stem cells: molecular analysis of cytotoxic T cell clones. Folia Histochem Cytobiol. 2007;45(1):5-14.
59. Koskela HL, Eldfors S, Ellonen P, van Adrichem AJ, Kuusanmaki H, Andersson EI, et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med. 2012;366(20):1905-13. doi:10.1056/NEJMoa1114885.
60. Strupp C, Gattermann N, Giagounidis A, Aul C, Hildebrandt B, Haas R, et al. Refractory anemia with excess of blasts in transformation: analysis of reclassification according to the WHO proposals. Leuk Res. 2003;27(5):397-404.
61. Huh YO, Jilani I, Estey E, Giles F, Kantarjian H, Freireich E, et al. More cell death in refractory anemia with excess blasts in transformation than in acute myeloid leukemia. Leukemia. 2002;16 (11):2249-52. doi:10.1038/sj.leu. 2402704.
62. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Gattermann N, Germing U, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol. 2010;28(4):562-9. doi:10.1200/JCO.2009.23. 8329.
63. Kasyan A, Medeiros LJ, Zuo Z, Santos FP, Ravandi-Kashani F, Miranda R, et al. Acute erythroid leukemia as defined in the World Health Organization classification is a rare and pathogenetically heterogeneous disease. Mod Pathol. 2010;23(8):1113-26. doi:10.1038/modpathol.2010.96.
64. Hasserjian RP, Zuo Z, Garcia C, Tang G, Kasyan A, Luthra R, et al. Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification. Blood. 2010;115(10):1985-92. doi:10.1182/blood-2009-09-243964.
65. Liu W, Hasserjian RP, Hu Y, Zhang L, Miranda RN, Medeiros LJ, et al. Pure erythroid leukemia: a reassessment of the entity using the 2008 World Health Organization classification. Mod Pathol. 2011;24(3):375-83. doi:10.1038/ modpathol.2010.194.
66. Park S, Picard F, Dreyfus F. Erythroleukemia: a need for a new definition. Leukemia. 2002;16(8):1399-401. doi:10.1038/sj.leu.2402549.
67. Dameshek W, Baldini M. The Di Guglielmo syndrome. Blood. 1958;13(2):192-4.
68. Hyjek E, Vardiman JW. Myelodysplastic/myeloproliferative neoplasms. Semin Diagn Pathol. 2011;28(4):283-97.
69. Patnaik MM, Lasho TL, Hodnefield JM, Knudson RA, Ketterling RP, Garcia-Manero G, et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood. 2012;119(2):569-72. doi:10.1182/blood-2011-09-377994.
70. Gattermann N, Aul C, Schneider W. Two types of acquired idiopathic sideroblastic anaemia (AISA). Br J Haematol. 1990;74 (1):45-52.
71. Cotter PD, May A, Fitzsimons EJ, Houston T, Woodcock BE, al-Sabah AI, et al. Late-onset X-linked sideroblastic anemia. Missense mutations in the erythroid delta-Aminolevulinate synthase (ALAS2) gene in two pyridoxine-responsive patients initially diagnosed with acquired refractory anemia and ringed sideroblasts. J Clin Invest. 1995;96(4):2090-6. doi:10.1172/JCI118258.
72. FlemingMD. Congenital sideroblastic anemias: iron and heme lost in mitochondrial translation. Hematology Am Soc Hematol Educ Program. 2011;2011:525-31. doi:10.1182/asheducation-2011.1.525.
73. Baumann Kreuziger LM, Wolanskyj AP, Hanson CA, Steensma DP. Lack of efficacy of pyridoxine (vitamin B6) treatment in acquired idiopathic sideroblastic anaemia, including refractory anaemia with ring sideroblasts. Eur J Haematol. 2011;86(6):512-6. doi:10.1111/j.1600-0609.2011.01604.x.
74. Colucci G, Silzle T, Solenthaler M. Pyrazinamide-induced sideroblastic anemia. Am J Hematol. 2012;87(3):305. doi:10.1002/ajh.22125.
75. Kumar N, ElliottMA, Hoyer JD, Harper Jr CM, Ahlskog JE, Phyliky RL. "Myelodysplasia," myeloneuropathy, and copper deficiency. Mayo Clin Proc. 2005;80(7):943-6. doi:10.4065/80.7.943.
76. Haddad AS, Subbiah V, Lichtin AE, Theil KS, Maciejewski JP. Hypocupremia and bone marrow failure. Haematologica. 2008;93 (1):e1-5. doi:10.3324/haematol. 12121.
77. Yang DT, Cook RJ. Spurious elevations of vitamin B12 with pernicious anemia. N Engl J Med. 2012;366(18):1742-3. doi:10.1056/NEJMc1201655. Clinicians should be aware that serum vitamin B12 measurements may be spuriously elevated with certain new automated analyzers, due to blocking of the immunoassay by intrinsic factor.
78. Latvala J, Parkkila S, Niemela O. Excess alcohol consumption is common in patients with cytopenia: studies in blood and bone marrow cells. Alcohol Clin Exp Res. 2004;28(4):619-24.
79. Ballard HS. The hematological complications of alcoholism. Alcohol Health Res World. 1997;21(1):42-52.
80. Rezuke WN, Anderson C, Pastuszak WT, Conway SR, Firshein SI. Arsenic intoxication presenting as a myelodysplastic syndrome: a case report. Am J Hematol. 1991;36(4):291-3.
81. Pande A, Bhattacharyya M, Pain S, Samanta A. Study of bone marrow changes in antiretroviral naive human immunodeficiency virus-infected anemic patients. Indian J Pathol Microbiol. 2011;54 (3):542-6. doi:10.4103/0377-4929.85089.
82. Ryu T, Ikeda M, Okazaki Y, Tokuda H, Yoshino N, Honda M, et al. Myelodysplasia associated with acquired immunodeficiency syndrome. Intern Med. 2001;40(8):795-801.
83. Tripathi AK, Kalra P, Misra R, Kumar A, Gupta N. Study of bone marrow abnormalities in patients with HIV disease. J Assoc Physicians India. 2005;53:105-10.
84. Steensma DP, Tefferi A, Li CY. Splenic histopathological patterns in chronic myelomonocytic leukemia with clinical correlations: reinforcement of the heterogeneity of the syndrome. Leuk Res. 2003;27(9):775-82.
85. Mastrodemou S, Vazgiourakis V, Velegraki M, Pavlaki K, Goulielmos GN, Papadaki HA. Clonal patterns of X-chromosome inactivation in peripheral blood cells of female patients with chronic idiopathic neutropenia. Haematologica. 2012. doi:10.3324/haematol.2012.069310.